FDA Warning Letter highlights risks of using AI in drug manufacturing | DLA Piper - JD Supra
To be clear, FDA does not prohibit the use of AI to assist with cGMP activities. However, this Warning Letter demonstrates the risks of overreliance ...
Read the original at JDSupra ↗
- Topics
- HealthcareManufacturing & Robotics
- Mentions
- FDA
- Tracked via
- “AI Risks”
Same story, other outlets
- FDA Warning Letter highlights risks of using AI in drug manufacturing | DLA Piper DLA Piper · Apr 22, 2026